Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT00504270
A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00502671
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 801
- Registration Number
- NCT00503113
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 193
- Registration Number
- NCT00502840
- Locations
- 🇩🇪
Rheumapraxis - Dres. Edmund Edelmann, Gerhard Straeßner und Hans Bloching, Bad Aibling, Germany
🇩🇪Campus Charité Mitte Charité Centrum 12. Med.Klinik Abt.Rheumatologie u.Klin.Immunologie, Berlin, Germany
🇩🇪Praxis Dr. Silke Zinke, Berlin, Germany
A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 289
- Registration Number
- NCT00502710
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT00502736
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 246
- Registration Number
- NCT00502996
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT00502853
- Locations
- 🇮🇹
Università Degli Studi Di Genova - Dimi; Reumatologia, Genova, Liguria, Italy
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 215
- Registration Number
- NCT00503425
- Locations
- 🇮🇱
Carmel Hospital; Rheumatology Dept, Haifa, Israel
🇮🇱Meir Medical Center; Internal Dept A, Kfar Saba, Israel
🇮🇱EMMS Nazareth; Internal Department A, Nazareth, Israel
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 159
- Registration Number
- NCT00496457
- Locations
- 🇭🇷
Genaral Hospital "Josip Bencevic", Internal Medicine Department-Unit for Diabetes, Andrije Stampara 42, Slavonski Brod, Croatia
🇭🇷General Hospital Varazdin, Internal Medicine Department-Unit for Diabetes, Ivana Mestrovica bb, Varazdin, Croatia
🇷🇸Center for Neurology, Clinical Centre "Kragujevac", Kragujevac, Serbia